Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Expression of MECOM is associated with unfavorable prognosis in glioblastoma multiforme

Tytuł:
Expression of MECOM is associated with unfavorable prognosis in glioblastoma multiforme
Autorzy:
Hou AW
Zhao LZ
Zhao FZ
Wang WL
Niu JY
Li BX
Zhou ZJ
Zhu DY
Temat:
MECOM
glioblastoma multiforme
progression
prognosis
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Źródło:
OncoTargets and Therapy, Vol 2016, Iss Issue 1, Pp 315-320 (2016)
Wydawca:
Dove Medical Press, 2016.
Rok publikacji:
2016
Kolekcja:
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Typ dokumentu:
article
Opis pliku:
electronic resource
Język:
English
ISSN:
1178-6930
Relacje:
https://www.dovepress.com/expression-of-mecom-is-associated-with-unfavorable-prognosis-in-gliobl-peer-reviewed-article-OTT; https://doaj.org/toc/1178-6930
Dostęp URL:
https://doaj.org/article/6323ac21ee9a4c8a844ac16b1d1d126f  Link otwiera się w nowym oknie
Numer akcesji:
edsdoj.6323ac21ee9a4c8a844ac16b1d1d126f
Czasopismo naukowe
Aiwu Hou,1,* Lizhen Zhao,1,* Fuzhen Zhao,2 Weiliang Wang,3 Jianyi Niu,1 Bingxuan Li,1 Zhongjin Zhou,1 Dongyuan Zhu4 1Department of Neurology, Yidu Central Hospital of Weifang City, 2Department of Orthopedics, People’s Hospital of Qingzhou City, 3Department of Psychiatrics, People’s Third Hospital of Weifang City, Weifang, 4Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences *These authors contributed equally to this work Background: MDS1 and EVI1 complex locus protein EVI1 (MECOM) is an oncogenic transcription factor in several kinds of cancers. However, the clinical significance of MECOM in glioblastoma multiforme (GBM) has not been well elucidated.Patients and methods: Our study enrolled 86 resected samples of GBM in three medical centers. We detected the expression of MECOM in all the 86 samples by immunohistochemistry and compared the difference of MECOM mRNA between tumor tissues and adjacent tissues with real-time polymerase chain reaction. With immunoblotting, we detected the MECOM expression in different GBM cell lines. Moreover, we analyzed the correlation between MECOM expression and clinicopathologic factors with chi-square test, and evaluated the prognostic value of MECOM with univariate and multivariate analysis.Results: In GBM tissue, the percentage of MECOM high expression is 41.9% (36/86). The mRNA of MECOM in tumor tissues is remarkably higher than that in adjacent tissues, indicating the oncogenic role of MECOM in GBM. MECOM exists in all the detected cell lines with different abundance. Moreover, MECOM is correlated with poorer overall survival rate (P=0.033) and can be identified as an independent prognostic factor in GBM (P=0.042).Conclusion: MECOM could be considered as an independent prognostic factor in GBM, predicting it as a potential and promising molecular drug target. Keywords: MECOM, glioblastoma multiforme, progression, prognosis

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies